| 20.65 0 (0%) | 03-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.39 | 1-year : | 25.06 |
| Resists | First : | 20.88 | Second : | 21.45 |
| Pivot price | 20.86  |
|||
| Supports | First : | 19.95 | Second : | 16.6 |
| MAs | MA(5) : | 20.75 |
MA(20) : | 20.8 |
| MA(100) : | 17.62 |
MA(250) : | 15.85 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 14.4 |
D(3) : | 25.6 |
| RSI | RSI(14): 50.1 | |||
| 52-week | High : | 27.36 | Low : | 7.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OPNT ] has closed above bottom band by 8.3%. Bollinger Bands are 83.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.67 - 20.77 | 20.77 - 20.86 |
| Low: | 20.4 - 20.52 | 20.52 - 20.63 |
| Close: | 20.48 - 20.66 | 20.66 - 20.81 |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Sun, 07 Apr 2024
Investing in Opiant Pharmaceuticals (NASDAQ:OPNT) five years ago would have delivered you a 279% gain - Yahoo Movies UK
Thu, 02 Mar 2023
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. - PR Newswire
Wed, 22 Feb 2023
Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership ... - Yahoo Finance
Sat, 11 Feb 2023
What's The Opiant CVR Worth? (NASDAQ:OPNT) - Seeking Alpha
Thu, 19 Jan 2023
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for ... - GlobeNewswire
Mon, 14 Nov 2022
Opiant (OPNT) Stock Skyrockets on Indivior's $145M Buyout Offer - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 43.2 (%) |
| Shares Short | 28 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0.5 |
| EPS Est Next Year | 1.25 |
| Book Value (p.s.) | 8.34 |
| Profit Margin | -148.2 % |
| Operating Margin | -141.1 % |
| Return on Assets (ttm) | -35.6 % |
| Return on Equity (ttm) | -105.9 % |
| Qtrly Rev. Growth | -99 % |
| Gross Profit (p.s.) | 4.15 |
| Sales Per Share | 4.23 |
| EBITDA (p.s.) | -5.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -46.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.47 |
| Price to Sales | 4.87 |
| Price to Cash Flow | -7.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|